Cargando…
mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we...
Autores principales: | Chiang, Chun-Te, Demetriou, Alexandra N., Ung, Nolan, Choudhury, Niharika, Ghaffarian, Kimya, Ruderman, Daniel L., Mumenthaler, Shannon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443389/ https://www.ncbi.nlm.nih.gov/pubmed/30036610 http://dx.doi.org/10.1016/j.canlet.2018.07.025 |
Ejemplares similares
-
Multiplexed imaging and effluent analysis to monitor cancer cell intravasation using a colorectal cancer-on-chip
por: Strelez, Carly, et al.
Publicado: (2021) -
Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013) -
Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015) -
mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)